Clinical Trial Update: A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker [Phase 3]

View source ↗

Summary

A Phase 3 trial of dapagliflozin (BMS-512148) in adults with type 2 diabetes and inadequately controlled hypertension on an ACE inhibitor or ARB has completed. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Type 2 Diabetes Mellitus

Drugs mentioned

• Dapagliflozin (dapagliflozin)
• FARXIGA (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2014-05-01